A Study for Schizophrenia Relapse Prediction

Completed

Brief Summary: The purpose of this study is to identify if there are self-reported/caregiver reported or objective measures that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of pre-relapse.

Recruitment & Eligibility

Inclusion Criteria

Participants and their legally acceptable representative where applicable must be able to sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and is willing to participate for the duration of the study
Have a clinical diagnosis of schizophrenia made by a clinician with understanding of the criteria for schizophrenia or schizoaffective disorder, per the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5), and had at least 1 relapse, in the opinion of the investigator, within the last 12 months prior to date of informed consent
Must be receiving an OAP treatment regimen at the time of enrollment
Must be able to speak, read, and understand English and/or the local Indian language as the patient reported outcome instruments will be validated in regional languages
Caregivers/Informants should be able to sign an ICF indicating that he or she understands the purpose of and procedures required for the study and is willing to participate for the duration of the study

Exclusion Criteria

Has treatment resistant schizophrenia (that is, currently receiving clozapine or electroconvulsive therapy [ECT])
Is on long-acting injectable antipsychotic regimen at the time of screening
Has a moderate to severe substance use disorder (other than nicotine), as determined by the investigator
Has a significant risk of suicide or active suicidality with a plan as indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS) assessment
Has an immediate need for hospitalization (that is, the participant is already in a relapse)

Arm && Interventions

Group	Intervention	Description
Participants with Schizophrenia	Oral Antipsychotics (OAP)	Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram \[mg\] once daily \[OD\] to twice a day \[BID\]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day \[TID\]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Relapse	Up to Approximately 3 years	Relapse is defined as achieving any of the following: clinically meaningful worsening of symptoms as determined by the treating physician's judgment; involuntary or voluntary admission to a psychiatric hospital for decompensation of the participant's schizophrenic symptoms (psychiatric hospitalization); deliberate self-injury and/or violent behavior resulting in clinically significant injury to the participant or another person or property damage; suicidal or homicidal ideation and aggressive behavior considered as clinically significant (in frequency and severity) in the treating physician's judgment; an increase of at least 2 points from the lowest reported Clinical Global Impression-Severity (CGI-S) score (ranging from 1 \[not ill\] to 7 \[extremely severe\]) captured either at baseline or post baseline. Number of participants with relapse will be determined.

Secondary Outcome Measures

Name	Time	Method
Number of Participants in each Clinical State of Schizophrenia	Up to approximately 3 years	Number of participants in each clinical state (Acute, Stable, and Remission) of schizophrenia will be assessed. The clinical states are defined as: 'Acute' - Clinical Global Impression-Severity (CGI-S) score (ranging from 1 \[not ill\] to 7 \[extremely severe\]) greater than or equal to (\>=)5 anytime during the study; 'Stable' (Tier I) - control of acute symptoms, defined as having a CGI-S score of less than or equal to (\<=)3 for a minimum of 3 months and/or (Tier II) - stable dosage of oral antipsychotic (OAPs) for a minimum of 3 months and control of acute symptoms, defined as having a CGI-S score of \<=4 for a minimum of 3 months; and 'Remission' - a continuous CGI-S scale score of \<=2 for 6 months.

Locations (10): Asha hospital
🇮🇳
Hyderabad, India
Mahendru Psychiatric Centre
🇮🇳
Kanpur, India
Panchshil Hospital
🇮🇳
Ahmedabad, India
GMERS Medical College and Hospital
🇮🇳
Vadodara, India
Meera Hospital
🇮🇳
Mumbai, India
Ratandeep Multispeciality Hospital
🇮🇳
Ahmedabad, India
Ahana Hospitals
🇮🇳
Madurai, India
Kasturba Medical College Hospital
🇮🇳
Manipal, India
Meditrina Institute of Medical Sciences
🇮🇳
Nagpur, India
Deva Institute of Health Care and Research Pvt Ltd
🇮🇳
Varanasi, India